Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809341 | 0.79 | CYP2D6 (0.59) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL11883845 | 0.78 | CYP2D6 (0.57) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL4563568 | 0.78 | CYP2D6 (0.57) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL7815004 | 0.75 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL659768 | 0.75 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL7824857 | 0.75 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL11315838 | 0.75 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL14935824 | 0.74 | CYP2D6 (0.42) | CYP2D6SRCLMNAMAPK1GRM2 | |
| SCHEMBL6451941 | 0.74 | CYP2D6 (0.42) | CYP2D6SRCLMNAMAPK1GRM2 | |
| SCHEMBL6451939 | 0.74 | CYP2D6 (0.42) | CYP2D6SRCLMNAMAPK1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417433-A | Preparation method and application of empty MHCI | 天津大学 | 2024-01-19 | — | — | CN | claimed |
| CN-117417433-A | Preparation method and application of empty MHCI | 天津大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-115776987-A | Barcoded exchangeable peptide-MHC multimer libraries | 瑞佩尔托利免疫医药股份有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-112005115-A | Methods of characterizing multiple analytes from a single cell or cell population | 10X基因组学有限公司 | 2020-11-27 | — | — | CN | disclosed |
| US-20100183658-A1 | Novel Compounds for Enhancing MHC Class II Therapies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183658-A1 | Novel Compounds for Enhancing MHC Class II Therapies | HLA-DRB1, CD74, MICA | CYP2D6 2866/4885SRC 3466/4885LMNA 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.